4.8 Article

Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases

Journal

GASTROENTEROLOGY
Volume 152, Issue 2, Pages 351-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2016.09.046

Keywords

Intestine; Efficacy; Dose; Control

Funding

  1. Merck
  2. AbbVie
  3. Janssen
  4. Genentech
  5. Mitsubishi
  6. Ferring
  7. Norgine
  8. Tillots
  9. Vifor
  10. Therakos
  11. Pharmacosmos
  12. Pilege
  13. BMS
  14. UCB-pharma
  15. Hospira
  16. Celltrion
  17. Takeda
  18. Biogaran
  19. Boehringer-Ingelheim
  20. Lilly
  21. Pfizer
  22. HAC-Pharma
  23. Index Pharmaceuticals
  24. Amgen
  25. Sandoz
  26. Forward Pharma GmbH
  27. Celgene
  28. Biogen
  29. Lycera
  30. Samsung Bioepis
  31. HACpharma
  32. Merck
  33. AbbVie
  34. Janssen
  35. Genentech
  36. Mitsubishi
  37. Ferring
  38. Norgine
  39. Tillots
  40. Vifor
  41. Therakos
  42. Pharmacosmos
  43. Pilege
  44. BMS
  45. UCB-pharma
  46. Hospira
  47. Celltrion
  48. Takeda
  49. Biogaran
  50. Boehringer-Ingelheim
  51. Lilly
  52. Pfizer
  53. HAC-Pharma
  54. Index Pharmaceuticals
  55. Amgen
  56. Sandoz
  57. Forward Pharma GmbH
  58. Celgene
  59. Biogen
  60. Lycera
  61. Samsung Bioepis
  62. HACpharma

Ask authors/readers for more resources

Strategies for management of inflammatory bowel diseases are shifting from simple control of symptoms toward full control of these diseases (clinical and endoscopic remission), with the final aim of blocking their progression and preventing bowel damage and disability. New goals have been proposed for treatment, such as treat to target and tight control based on therapeutic monitoring and early intervention. For patients who achieve clinical remission, there is often interest in discontinuation of therapy due to safety or economic concerns. We review the evidence supporting these emerging paradigms, the reasons that early effective treatment can alter progression of inflammatory bowel diseases, the importance of examining objective signs of inflammation, and the safety of reducing treatment dosage. We also discuss recent findings regarding personalization of care, including factors that predict patient outcomes and response to therapies, as well as preventative strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available